• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IBIO

    iBio Inc.

    Subscribe to $IBIO
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

    IPO Year:

    Exchange: AMEX

    Website: ibioinc.com

    Peers

    $AEMD

    Recent Analyst Ratings for iBio Inc.

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    See more ratings

    iBio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on iBio with a new price target

      Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

      5/28/24 7:42:07 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

      11/29/21 7:34:24 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

      11/29/21 7:32:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on iBio

      Cantor Fitzgerald initiated coverage of iBio with a rating of Overweight and set a new price target of $3

      1/22/21 6:01:33 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on iBio

      Cantor Fitzgerald initiated coverage of iBio with a rating of Overweight and set a new price target of $3

      1/21/21 4:07:05 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on iBio

      Cantor Fitzgerald initiated coverage of iBio with a rating of Overweight and set a new price target of $3

      1/21/21 4:07:05 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. SEC Filings

    See more
    • SEC Form D filed by iBio Inc.

      D - iBio, Inc. (0001420720) (Filer)

      5/7/25 9:50:45 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by iBio Inc.

      10-Q - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:29:28 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:05:54 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by iBio Inc.

      424B5 - iBio, Inc. (0001420720) (Filer)

      4/30/25 8:01:36 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by iBio Inc.

      424B5 - iBio, Inc. (0001420720) (Filer)

      4/30/25 8:01:19 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by iBio Inc.

      424B5 - iBio, Inc. (0001420720) (Filer)

      4/30/25 8:00:46 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      4/22/25 4:41:30 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      4/8/25 7:30:37 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      4/7/25 7:01:51 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by iBio Inc.

      25 - iBio, Inc. (0001420720) (Filer)

      3/3/25 4:05:23 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      11/14/24 8:47:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iBio Inc.

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      11/14/24 4:48:52 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by iBio Inc. (Amendment)

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      4/9/24 5:22:43 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      4/8/24 8:18:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      4/5/24 5:11:14 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      4/1/24 7:23:24 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      1/4/24 8:00:38 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      2/9/23 11:22:21 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      7/8/22 4:57:04 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    iBio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

      Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in Janu

      5/5/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Third Quarter 2025 Financial Results

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. "During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "At the same time, we made significant strides in our pipeline, with promising non

      5/2/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Raises $6.2 Million Through Warrant Inducement Transaction

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for worki

      4/29/25 1:43:30 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

      SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-

      4/22/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

      Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company's novel lead asset and a potenti

      4/7/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Second Quarter 2025 Financial Results

      SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. "In our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics," said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. "Following more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel

      2/10/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Announces New Investments from Board Members and Officers

      SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board of Directors and Officers, totaling over $650,000. "We are grateful for the investments from our Board of Directors, which underscore their confidence and support in our strategy to advance as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases, obesity, and other challenging diseases," said Martin Brenner, Ph.D., DVM, CEO and Chief Scientific Officer. iBio is building an innovative pipeline of therapeutics in cardiometabolic di

      1/13/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

      SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio's patented Machine-Learning Antibody Engine. Developing an antibody against Activin E, a challenging and elusive target, highlights the robust capabilities of the technology to deliver innovative therapeutics, and contributes to iBio's pipeline of development candidates. iBio plans to rapidly advance testing of this molecule and additional candidates in

      1/7/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

      SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio's proprietary technology stack and was designed for subcutaneous administration with the potential for an extended half-life. Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio wi

      1/2/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Banjak Marc

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:01:30 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Duran Felipe

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:59 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Brenner Martin

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:12 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Arkowitz David bought $49,999 worth of shares (18,382 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:32:54 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Clark William D bought $4,999 worth of shares (1,838 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:31:25 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parada Antonio Bernardino Guimaraes bought $499,999 worth of shares (183,823 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:30:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sender Gary bought $25,000 worth of shares (9,191 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:30:14 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Arkowitz David bought $49,999 worth of shares (18,382 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:32:54 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Clark William D bought $4,999 worth of shares (1,838 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:31:25 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parada Antonio Bernardino Guimaraes bought $499,999 worth of shares (183,823 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:30:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sender Gary bought $25,000 worth of shares (9,191 units at $2.72) (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:30:14 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Strengthens Board with Appointment of Two New Independent Directors

      SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

      11/25/24 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2025 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

      11/12/24 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

      SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business development. Ms. Sarno brings more than 25 years of business development and strategic experience in the life sciences industry to iBio and will play a key role on the leadership team in establishing the company's corporate strategy and leading business development activities, including overseeing search and evaluation and transaction execution. Before joining iBio, Ms. Sarno held key positions in business development, strategic alliance, program management and research at lead

      8/12/24 4:30:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

      – Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately. Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020. The permanent appointments reflect the Board of Directors' confidence in Dr. Brenner and Mr. Duran, who have respectively served as iBio's interim CEO

      6/27/23 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

      Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development. "I am pleased to welcome Eef Schimmelpennink to Pipeline's Board of Directors," said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. "Eef is a renowned leader in the life-sciences industry whose cross-functional leade

      2/15/22 8:00:00 AM ET
      $IBIO
      $PFNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • iBio Announces Partial Adjournment of Annual Meeting to December 22

      - Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - BRYAN, Texas, Dec. 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its annual meeting of stockholders (the "Annual Meeting") scheduled for and convened yesterday has been partially adjourned to December 22, 2021 at 9:00 a.m. Eastern Time. A quorum was present at yesterday's Annual Meeting, and Proposals 1 (election of directors), 2 (appointment of auditors) and 3 (Say-on-Pay) put forth in the definitive

      12/10/21 8:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink

      BRYAN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today the appointment of Evert (Eef) Schimmelpennink to its Board of Directors, effective immediately. In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has applied his strategic and functional expertise across corporate development, commercial operations, manufacturing, and R&D to help build and scale a number of global public and private biopharmaceutical businesses. Recently, he served as CEO of Pfenex Inc., a NYSEA-listed company which, using its patented Pfēnex Expression T

      6/9/21 4:30:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Appoints Robert M. Lutz as Chief Financial & Business Officer

      BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (“CFBO”), effective March 4, 2021. “I am pleased to welcome Rob to iBio where we expect he will make an immediate impact on our business during this transformative time,” said Tom Isett, Chairman & CEO of iBio. “His deep experience across corporate finance and business development functions, breadth of public company experience, and demonstrated expertise in building product portfolios is a tremendous fit for iBio as we seek to exe

      2/16/21 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

      BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation,

      12/28/20 7:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    iBio Inc. Financials

    Live finance-specific insights

    See more
    • iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

      – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

      3/27/24 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. "We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focus on developing innovative immunotherapies," said Tom Isett, Chairman & CEO of iBio. "Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug di

      9/27/22 4:10:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

      – Positions Company for leadership in AI-powered drug discovery – – Expands iBio's immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ("RubrYc") after it entered into a definitive asset purchase agreement (the

      9/21/22 8:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces its financial results for the fiscal quarter ended March 31, 2022 and provides a corporate update. "In this quarter, we took multiple steps forward towards becoming a clinical-stage company – a potentially major value inflection point," said Tom Isett, Chairman & CEO of iBio. "We anticipate there may be a notable medical and business opportunity for our nucleocapsid-based COVID-19 vaccine candidate, as the durability and efficacy of the existing spike-based vacc

      5/12/22 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

      BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 third quarter financial results after market close on Thursday, May 12, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Company's website at www.ibioinc.com under "News and Events" in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domes

      5/5/22 4:30:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update. "We are pleased to report that we have now added six new immuno-oncology assets to our pipeline in the six months since we announced our new drug discovery capabilities," said Tom Isett, Chairman & CEO of iBio. "Our most recent addition progressed the fastest, already advancing into late-discovery stage thanks to our deployment of artificial intelligence design

      2/14/22 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

      BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Company's website at www.ibioinc.com under "News and Events" in the Investors section. The live call can be accessed by dialing (833) 672-0651

      2/7/22 4:30:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

      - Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks - - Omicron's Many Mutations Occur in Regions Outside Those of IBIO-202's Nucleocapsid Antigen - - Company Expecting Feedback from U.S. FDA on IBIO-202 in January - BRYAN, Texas, Nov. 29, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2. On November 26, 2021, the World Health Organization's ("WHO") Technical Advisor

      11/29/21 8:45:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

      - Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research Collaboration with UT Southwestern to Study Anti-fibrotics in Oncology -   - Establishes Partnership for Development of Painless Intradermal Vaccine Delivery - BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended September 30, 2021 and provides a corporate update. "We are continuing to accelerate the execution of our growth strategy as we start o

      11/15/21 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

      BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 first quarter financial results after market close on Monday, November 15, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Company's website at www.ibioinc.com under "News and Events" in the Investors section. The live call can be accessed by dialing (833) 672-0651 (d

      11/8/21 4:30:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care